Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib

BACKGROUND: Patients with epidermal growth factor receptor (EGFR) activation mutation-positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase inhibitors (EGFR-TKIs), but eventually become resistant in most cases. The hepatocyte growth factor/c-Met (HGF/c-Met) pathway is repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Azuma, Koichi, Hirashima, Tomonori, Yamamoto, Nobuyuki, Okamoto, Isamu, Takahashi, Toshiaki, Nishio, Makoto, Hirata, Taizo, Kubota, Kaoru, Kasahara, Kazuo, Hida, Toyoaki, Yoshioka, Hiroshige, Nakanishi, Kaoru, Akinaga, Shiro, Nishio, Kazuto, Mitsudomi, Tetsuya, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070235/
https://www.ncbi.nlm.nih.gov/pubmed/27843623
http://dx.doi.org/10.1136/esmoopen-2016-000063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070235/
https://www.ncbi.nlm.nih.gov/pubmed/27843623
http://dx.doi.org/10.1136/esmoopen-2016-000063

Ejemplares similares